[
  {
    "ts": null,
    "headline": "UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know",
    "summary": "A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.",
    "url": "https://finnhub.io/api/news?id=0ce75ac5247ac6fd3dd8b3874f11308c1cc7d989193ebb28676594f5896c7a30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760125872,
      "headline": "UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know",
      "id": 137049031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.",
      "url": "https://finnhub.io/api/news?id=0ce75ac5247ac6fd3dd8b3874f11308c1cc7d989193ebb28676594f5896c7a30"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Friday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=dfa18e91a5b371c11febefa3fdf2f0e2aeecba06f01a10a8f61c87a36c7d7eaa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760115960,
      "headline": "Biogen Inc. stock underperforms Friday when compared to competitors",
      "id": 137118625,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=dfa18e91a5b371c11febefa3fdf2f0e2aeecba06f01a10a8f61c87a36c7d7eaa"
    }
  },
  {
    "ts": null,
    "headline": "Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?",
    "summary": "Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.",
    "url": "https://finnhub.io/api/news?id=f092b4eec61edf550771528c2a8bbf0674d0dddd12058cb766c63c4012a4d8e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760111700,
      "headline": "Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?",
      "id": 137049503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.",
      "url": "https://finnhub.io/api/news?id=f092b4eec61edf550771528c2a8bbf0674d0dddd12058cb766c63c4012a4d8e4"
    }
  },
  {
    "ts": null,
    "headline": "Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors",
    "summary": "The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker,Global Assurance Leader at PwC, to its board of directors, effective immediately.",
    "url": "https://finnhub.io/api/news?id=afdced71b03661a48eafaf18857434c718e227a58483a375449968f584a2f2bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760104800,
      "headline": "Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors",
      "id": 137042310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker,Global Assurance Leader at PwC, to its board of directors, effective immediately.",
      "url": "https://finnhub.io/api/news?id=afdced71b03661a48eafaf18857434c718e227a58483a375449968f584a2f2bc"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Biogen’s Q3 2025 Earnings Report",
    "summary": "Biogen is slated to release its fiscal third-quarter earnings later this month, and analysts are expecting its earnings to drop in the single-digit range.",
    "url": "https://finnhub.io/api/news?id=9c8af757930b9b40b61290c77578ca1fdade25187bc05c0cb5c66d702db08ba4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760085396,
      "headline": "What to Expect From Biogen’s Q3 2025 Earnings Report",
      "id": 137042312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen is slated to release its fiscal third-quarter earnings later this month, and analysts are expecting its earnings to drop in the single-digit range.",
      "url": "https://finnhub.io/api/news?id=9c8af757930b9b40b61290c77578ca1fdade25187bc05c0cb5c66d702db08ba4"
    }
  },
  {
    "ts": null,
    "headline": "Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome",
    "summary": "Biogen Inc. and Stoke Therapeutics announced new longer-term data from open-label extension studies of zorevunersen, showing sustained improvements in cognition, behavior, and overall clinical status for patients with Dravet syndrome, presented at the 54th Child Neurology Society Annual Meeting. Importantly, these results contrast with minimal changes seen in natural history controls and highlight zorevunersen's potential as a disease-modifying therapy in this rare epilepsy disorder. We'll...",
    "url": "https://finnhub.io/api/news?id=3de717281b99f47b5e7a55a5e804af96bb8bbe8b06413e97007202d3e3f97304",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760065787,
      "headline": "Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome",
      "id": 137042313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. and Stoke Therapeutics announced new longer-term data from open-label extension studies of zorevunersen, showing sustained improvements in cognition, behavior, and overall clinical status for patients with Dravet syndrome, presented at the 54th Child Neurology Society Annual Meeting. Importantly, these results contrast with minimal changes seen in natural history controls and highlight zorevunersen's potential as a disease-modifying therapy in this rare epilepsy disorder. We'll...",
      "url": "https://finnhub.io/api/news?id=3de717281b99f47b5e7a55a5e804af96bb8bbe8b06413e97007202d3e3f97304"
    }
  }
]